A long history of clinical (neo)adjuvant studies investigated the use of dual ERBB2/HER2 blockade to increase pathologic complete response (pCR) rates and improve outcomes in ERBB2/HER2-positive early BC (EBC). The gene discussed is ERBB2; the disease is breast cancer.